Abstract:Abstract Background JAK inhibitors have demonstrated efficacy in ulcerative colitis (UC), Crohn’s disease (CD), and inflammatory arthritis. However, limited data exist on their effectiveness in treating extraintestinal manifestations (EIM) in patients with inflammatory bowel disease (IBD) in real-world scenarios. This multicenter, retrospective study aims to assess the efficacy of JAK inhibitors (JAKI), specifically tofacitinib or upadacitinib, in IBD patients with EIM. Methods This was a retrospective multicenter cohort study. Inclusion criteria included IBD patients with active EIM documented before JAKI treatment initiation, with a follow-up up to 52 weeks. EIM Clinical response was defined as either improvement or remission of EIM complaints, as subjectively described by the patient or taken from the treating physician’s assessment. Results Eighty-six patients from eight centers were included, with 64% having UC (n=55). Women constituted 60% of the patients (n=51). Tofacitinib and upadacitinib were administered to 63% (n=54/86) and 36% (n=32/86) of patients, respectively. Eleven patients (13%) were biologically naïve, all treated with tofacitinib. Arthralgia was the predominant complaint, affecting 55% (n=30/54) of tofacitinib-treated and 44% (n=14/32) of upadacitinib-treated patients. Patient characteristics, including EIM distribution, are detailed in Table 1. At 3 months, 86% (n=72/83) achieved EIM clinical response, with tofacitinib responders at 94% (n=49/52) compared to 74% (n=23/31) for upadacitinib (p=0.01). Seven percent (n=6) discontinued treatment due to lack of response. Peripheral arthralgia improved or achieved remission in 86% (n=32/38) of patients, while 68% (n=13/19) with axial arthropathy experienced clinical response. At 6 months, EIM clinical response was achieved by 76% (n=44/75), with tofacitinib at 86% (n=44/51) and upadacitinib at 54% (n=13/24) (p=0.004). Twelve percent(n=10) discontinued treatment due to loss of response. Peripheral arthralgia responded in 86% (n=31/36), and axial arthropathy responded in 42% (n=8/19). At 12 months, 65% (n=44/68) of patients improved or had remission, with tofacitinib responders at 73% (n=35/48) and upadacitinib responders at 45% (n=9/20) (p<0.05). Eighty-eight percent (n=23/26) with peripheral arthralgia and 50% (n=5/10) with axial arthropathy achieved clinical response. Conclusion This study demonstrates the effectiveness of JAK inhibitors in treating EIM, with a high percentage of responders. Tofacitinib appears more effective than upadacitinib, possibly influenced by a higher proportion of biologically experienced patients and differences in IBD subtype distribution between the two groups, with upadacitinib mainly used in CD patients and tofacitinib in UC patients.

Impaired IFN-γ-dependent STAT3 Activation Is Associated With Dysregulation of Regulatory and Inflammatory Signaling in Monocytes of Ulcerative Colitis Patients

Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn's disease

P026 Differential effects of tofacitinib on macrophage activation may contribute to lack of response in ulcerative colitis patients

The JAK1/3 inhibitor tofacitinib suppresses T cell homing and activation in chronic intestinal inflammation.

Tofacitinib inhibits inflammatory cytokines from ulcerative colitis and healthy mucosal explants and is associated with pSTAT1/3 reduction in T-cells

JAK/STAT inhibition modifies the ILC1 immune response in patients with rheumatoid arthritis

Histological Outcomes and JAK-STAT Signalling in Ulcerative Colitis Patients Treated with Tofacitinib

Discordant effects of Janus kinases inhibition ex-vivo on inflammatory responses in colonic compared to ileal mucosa

Understanding the mechanisms underlying the lack of response to Janus kinase inhibition in ulcerative colitis

Effect of tofacitinib on the phenotype and activity of Caco‐2 cells in a model of inflammatory bowel disease

Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response

The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development

Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program

P663 Efficacy of jak inhibitors in inflammatory bowel disease patients with extraintestinal manifestations– Retrospective study

Delayed and limited administration of the JAKinib tofacitinib mitigates chronic DSS-induced colitis

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

P1024 The current role of Tofacitinib in acute severe ulcerative colitis in adult patients: A systematic review and pooled analysis

P083 JAK/STAT pathway and IL-6 activity in moderate to severe Ulcerative Colitis

CD1a-Expressing Monocytes as Mediators of Inflammation in Ulcerative Colitis

Suppression of IL‐12/IL‐23 p40 subunit in the skin and blood of psoriasis patients by Tofacitinib is dependent on active interferon‐γ signaling in dendritic cells: Implications for the treatment of psoriasis and interferon‐driven diseases

Tofacitinib uptake by patient-derived intestinal organoids predicts individual clinical responsiveness